Articles On Genetic Signatures (ASX:GSS)

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

GSS’s share price could almost triple, according to Taylor Collison Taylor also believes Good Drinks could outperform Shaw and Partners says it has a target price on Zip that’s 4x current share price   Genetic Signatures to nearly triple...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

ShareCafeWebinar Recap – T92, GSS, ORR & SPT Catch up on the full webinar with presentations from Terra Uranium (ASX: T92), Genetic Signatures (ASX: GSS), OrecORP (ASX: ORR) & Splitit (ASX: SPT) Webinar Recap – T92, GSS, ORR &...

ShareCafeGenetic Signatures (ASX: GSS) – webinar presentation John Melki – CEO and Director – Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platfo...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeThe Week that Was: November 14-18, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

ShareCafeGenetic Signatures (ASX: GSS) – Detecting Infectious Diseases in High-Throughput Lab Workflows   Genetic Signatures Limited (ASX: GSS) CEO and Director Dr John Melki discusses the company’s technology, business model, 2022 highlig...

ASX 200 closes with -1.8% loss Small cap index down -1.2% Up way more than 100% is Norfolk Minerals, the real NFL   Everyone in this part of the world seems pretty upset by the US Federal Reserve Chairman Jerome Powell – more so than the...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

As Maxwell Smart said: “Missed it by that much.” In Genetic Signatures’ (ASX:GSS) case, the close-but-no-cigar moment was its narrow June quarter loss of $169,000, which meant the company did not achieve four consecutive quarters of cash fl...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Nasdaq-listed Biogen says its experimental Alzheimer’s drug study was successful The news sends ASX-listed Cogstate to soar Orthocell could have the first FDA-approved injectable cell therapy in orthopaedics  Big news out of Nasdaq-listed...

Molecular diagnostics company Genetic Signatures (ASX:GSS) has completed recruitment for the clinical trial of its 3base EasyScreen Enteric Protozoan Diagnostic Kit in the US.

Genetic Signatures (GSS) completes recruitment for its 3base EasyScreen enteric protozoan diagnostic kit clinical trial in the US The EasyScreen enteric protozoan diagnostic kit uses GSS’ 3base technology to detect up to eight species of g...

INOVIQ reports good findings from feasibility study Mayne Pharma launches a unique oral contraceptive in the Aussie market Genetic Signatures has US FDA in its mind Diagnostics and exosome specialist INOVIQ (ASX:IIQ) – formerly called Bar...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Genetic Signatures (ASX:GSS) has announced a three-year contract to supply its EasyScreen genetic diagnostic kits and instruments to seven hospitals across Wales.

Genetic Signatures (GSS) has secured a three-year contract with Public Health Wales, worth up to $1.8 million per annum, with an option to extend for two years The contract will see the company supply its EasyScreen diagnostic kits and ins...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

In this week’s ScoPo’s Powerplays, healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, examines the turbulent start to 2022 for ASX health stocks and what could lie ahead as ge...

ShareCafeGenetic Signatures (ASX: GSS) – Webinar Presentation John Melki – CEO & Director – Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform...

ShareCafeWebinar Recap – GSS, LGP, ALA & RTH Catch up on the full webinar with presentations from Genetic Signatures (ASX: GSS),  Little Green Pharma (ASX: LGP),  Arovella Therapeutics (ASX: ALA)  & Quantum Graphite (ASX: QG...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 2.3%, while the benchmark ASX 200 is falling by 0.7%. Cannabis stock Little Green Pharma (ASX:LGP) has been awarded an Italian government tender to deliver a shipment of EU G...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. During his Australian Open quar...

Australia’s Therapeutic Goods Administration (TGA) registers a saliva-based protocol for testing samples using Genetic Signatures’ (GSS) 3base EasyScreen detection kit A recent study by scientists in South Africa demonstrated that saliva s...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.1% to 7,447.7 points. Four ASX shares that have not let that hold them back are l...

The Genetic Signatures Ltd (ASX: GSS) share price is on the move today after an update on the company’s COVID-19 test kit. Shares in the diagnostics company are swapping hands at $1.77 in afternoon trade, up 6.31%. Let’s take a look at w...

Among ASX health stocks with news, Genetic Signatures (ASX:GSS) caught the market’s attention with an update on its latest COVID-19 testing product. The diagnostics company confirmed Australia’s health regulator, the Therapeutic Goods Admin...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

Shares in molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) finished the day strong and closed 12.5% in the green at $1.75. Today’s gain extends an impressive run the company has been on over the past week. Specifically, inv...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Genetic Signatures (GSS) has released a wide-ranging update, revealing it’s expecting $21 million dollars in sales in 1H 2022 The company has created a new COVID-19 detection kit to differentiate between the Delta and Omicron variants GSS...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week With a slew o...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Power says...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

ShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with presentations from BPH Energy (ASX: BPH), Exopharm (ASX: EX1), RessApp (ASX: RAP) & Prescient Therapeutics (ASX: GSS) Hidden Gems Webinar Re...